Industries · Immuno-oncology
Immuno-oncology
OMICS4 runs the multi-omics profiling behind your tumor microenvironment studies (bulk and single-cell RNA-seq, immune profiling and biomarker sample workflows) via our in-house platforms.
Industries · Immuno-oncology
OMICS4 runs the multi-omics profiling behind your tumor microenvironment studies (bulk and single-cell RNA-seq, immune profiling and biomarker sample workflows) via our in-house platforms.
Overview
OMICS4 characterizes the tumor microenvironment through integrated multi-omics, helping translational teams generate the biomarker data linked to immune response and treatment outcome, run end-to-end via our in-house platforms.
OMICS4 capabilities
Tumor and immune compartments characterized at multiple layers.
Sample-level sequencing that feeds cell-type composition and subtype analysis.
Responder signatures validated across independent cohorts.
ML models and dashboards linking signatures to outcome, delivered by GenXMap's Computational Biology & AI layer on top of our wet-lab data.
How OMICS4 adapts
No two programs run the same workflow. Here is how OMICS4 fits into what you already have in place.
Samples are often scarce, heterogeneous biopsies collected across multiple clinical sites.
Protocols are built for low-input, FFPE-compatible, multi-site sample sets with harmonized QC.
Cohorts evolve over time as trials enroll: data needs to accumulate, not restart.
Processing is versioned so new patient batches are integrated into the existing cohort, not reprocessed from scratch.
Translational teams need results that connect back to clinical outcome and treatment arms.
Molecular findings are reported alongside your clinical/treatment metadata, not as a standalone omics dataset.
Regulatory and IRB constraints shape what data can move where.
Data handling is scoped to your consent and IRB framework from the outset.
Have a project in this space?